Survival following resection of pancreatic endocrine tumors: Importance of R-status and the WHO and TNM classification systems

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 7-8, 2010, Pages 971-979

  Pomianowska, Ewa ^a   Gladhaug, Ivar P ^a   Grzyb, Krzysztof ^a   Røsok, Brd I ^a   Edwin, Bjørn ^a   Bergestuen, Deidi S ^a   Mathisen, Øystein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Endocrine tumor; Pancreas; Prognosis; Surgery; Survival

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PANCREAS ISLET CELL TUMOR; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOLOGY; SURVIVAL; SURVIVAL TIME; TUMOR DIFFERENTIATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 77955684946     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521003782363     Document Type: Article

References (32)

1. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004;120:139-161
2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469-1492
3. O'Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur J Surg Oncol 2008;34:324-332
4. Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007;245:273-281
5. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009;115:741-751
6. Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg 2006;244:845-851
7. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753-781
8. Solcia E, Rindi G, Paolotti D, La RS, Capella C, Fiocca R. Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Ann Oncol 1999;10(Suppl 2):S9-15.
9. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-560
10. Rindi G, Kloppel G. Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 2004;80(Suppl 1):12-15
11. Bilimoria KY, Bentrem DJ, Merkow RP, Tomlinson JS, Stewart AK, Ko CY, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007;205:558-563
12. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
13. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol 2008;19:903-908
14. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798-7803
15. Bordi C, D'Adda T, Azzoni C, Pizzi S, Bottarelli L, Mormandi F, et al. Criteria for malignancy in gastrointestinal endocrine tumors. Endocr Pathol 2006;17:119-129
16. Fischer L, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, et al. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008;95:627-635
17. Phan GQ, Yeo CJ, Hruban RH, Littemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 1998;2:473-482
18. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078-1085
19. You DD, Lee HG, Paik KY, Heo JS, Choi SH, Choi DW. The outcomes after surgical resection in pancreatic endocrine tumors: An institutional experience. Eur J Surg Oncol 2009;35:728-733
20. Bloomston M, Muscarella P, Shah MH, Frankel WL, Al-Saif O, Martin EW, et al. Cytoreduction results in high perioperative mortality and decreased survival in patients undergoing pancreatectomy for neuroendocrine tumors of the pancreas. J Gastrointest Surg 2006;10:1361-1370
21. Pelosi G, Bresaola E, Bogina G, Pasini F, Rodella S, Castelli P, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating- cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996;27:1124-1134
22. Lloyd RV. Utility of Ki-67 as a prognostic marker in pancreatic endocrine neoplasms. Am J Clin Pathol 1998;109:245-247
23. Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J Mol Med 1998;76:413-420
24. Rigaud G, Missiaglia E, Moore PS, Zamboni G, Falconi M, Talamini G, et al. High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications. Cancer Res 2001;61: 285-292
25. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006;13:1213-1221
26. La RS, Rigoli E, Uccella S, Novario R, Capella C. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours. Histopathology 2007;50:597-606.
27. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12: 1083-1092
28. Deschamps L, Handra-Luca A, O'Toole D, Sauvanet A, Ruszniewski P, Belghiti J, et al. CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. Hum Pathol 2006;37:802-808
29. Clarke MR, Baker EE, Weyant RJ, Hill L, Carty SE. Proliferative activity in pancreatic endocrine tumors: association with function, metastases, and survival. Endocr Pathol 1997;8:181-187
30. Jamali M, Chetty R. Predicting prognosis in gastroenteropancreatic neuroendocrine tumors: an overview and the value of Ki-67 immunostaining. Endocr Pathol 2008; 19:282-288
31. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg 2006;93:1232-1237
32. Westgaard A, Laronningen S, Mellem C, Eide TJ, Clausen OP, Moller B, et al. Are survival predictions reliable? Hospital volume versus standardisation of histopathologic reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer 2009;45:2850-2859